Announcements Trials
Browse Landscape

Phase

Phase 1/2 10Phase 2 3Phase 1 1

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Carcinoma, Medullary 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × yeast-CEA vaccine × Clear all
NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01856920 2024-07-09

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NantCell, Inc.

Phase 2 Completed
35 enrolled 9 charts

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡